# FDA 21 CFR Part 11 Readiness Assessment: Score Your Electronic Records Compliance > Source: https://netray.co/tools/fda-21-cfr-part-11-readiness-assessment > Publisher: Netray (netray.co), AI and integration engineering for ERP and manufacturing systems. > Section: Free Tools ## Short answer Answer 8 questions on e-signatures, audit trails, access control, and validation status to see how ready your electronic records and systems are for FDA scrutiny. ## Category erp-operations ## Tool **Kind:** assessment **Questions:** #### How are electronic records for GxP-regulated processes signed and approved? **Help:** Consider batch records, quality records, and any document requiring a formal approval signature. **Options:** ##### Paper records with wet-ink signatures, or an unmanaged hybrid of paper and electronic **Score:** 0 ##### Basic electronic signature with no linked audit trail **Score:** 3 ##### Validated e-signature with audit trail, but review is manual and inconsistent **Score:** 6 ##### Fully validated e-signature system with automated audit trail and periodic review **Score:** 10 #### Do your systems maintain a secure, computer-generated, time-stamped audit trail of record creation, modification, and deletion? **Options:** ##### No audit trail exists for most GxP systems **Score:** 0 ##### Partial audit trail coverage for some systems only **Score:** 4 ##### Full audit trail for critical systems, reviewed occasionally **Score:** 7 ##### Full audit trail for all GxP systems with tamper-evident storage and scheduled review **Score:** 10 #### How is system access controlled for users who can create or modify electronic records? **Options:** ##### Shared logins or generic accounts are common **Score:** 0 ##### Individual logins exist but access is rarely reviewed **Score:** 4 ##### Individual logins with an annual access review **Score:** 7 ##### Individual logins, role-based access, MFA, and quarterly access review **Score:** 10 #### What is your validation status for computer systems used in regulated processes (CSV or risk-based CSA)? **Options:** ##### No formal validation documentation exists **Score:** 0 ##### Validation documents exist but are outdated or incomplete **Score:** 3 ##### Current validation exists for most in-scope systems **Score:** 7 ##### Current, risk-based validation exists for all in-scope systems **Score:** 10 #### How do you handle data integrity controls consistent with ALCOA+ principles across your quality systems? **Options:** ##### Not formally assessed against ALCOA+ **Score:** 0 ##### Assessed once, with known gaps still open **Score:** 4 ##### Assessed with a remediation plan actively in progress **Score:** 7 ##### Continuously monitored and enforced through system controls **Score:** 10 #### What is your process for detecting and investigating data integrity or audit trail anomalies? **Options:** ##### No process exists **Score:** 0 ##### Manual spot checks performed occasionally **Score:** 4 ##### Scheduled manual review of audit trail exceptions **Score:** 7 ##### Automated anomaly detection with a documented investigation workflow **Score:** 10 #### How prepared is your organization to produce a complete electronic record and audit trail package on FDA request? **Help:** Assume a request for a full record set with supporting audit trail across a specific date range. **Options:** ##### Unsure how, would likely take months to assemble **Score:** 0 ##### Possible within weeks with significant manual effort **Score:** 4 ##### Possible within days with moderate manual effort **Score:** 7 ##### Possible same day through an automated export **Score:** 10 #### Has your quality or IT team conducted a gap assessment against 21 CFR Part 11 in the last 12 months? **Options:** ##### Never conducted **Score:** 0 ##### More than 2 years ago **Score:** 3 ##### Within the last 1-2 years **Score:** 6 ##### Within the last 12 months **Score:** 10 **Bands:** #### High Exposure: Part 11 Gaps Likely to Draw a 483 **Min:** 0 **Max:** 40 **Verdict:** Your electronic records and signature controls have significant gaps that an FDA investigator would document as observations. Audit trail coverage, validation status, or access control are likely insufficient to withstand an inspection, and remediation should start immediately rather than waiting for the next scheduled audit. **Recommendations:** - Commission an independent Part 11 gap assessment across every GxP system within 90 days - Prioritize audit trail remediation for systems handling batch records and quality data first - Freeze new system rollouts until validation and access control gaps are documented and scheduled - Establish individual user logins with role-based access before any further remediation work - Engage regulatory counsel to assess exposure from any past inspections or complaints #### Developing: Foundational Controls Exist, Audit Trail Gaps Remain **Min:** 41 **Max:** 65 **Verdict:** You have foundational e-signature and access controls in place, but audit trail coverage, validation currency, or anomaly detection have meaningful gaps that would draw investigator attention. This is a common and fixable state, not a crisis, if addressed within the next 6-12 months. **Recommendations:** - Extend audit trail coverage to every system handling GxP records, not just the primary ones - Refresh validation documentation for any system last validated more than 18 months ago - Move from occasional manual audit trail review to a scheduled quarterly cadence - Build a documented process for investigating audit trail anomalies before the next audit #### Substantially Compliant: Tighten Monitoring and Validation Currency **Min:** 66 **Max:** 85 **Verdict:** Your core Part 11 controls, including e-signatures, audit trails, and access management, are largely in place. The remaining gap is typically monitoring cadence and keeping validation documentation current as systems change, both of which are operational discipline issues rather than architectural ones. **Recommendations:** - Move audit trail exception review to an automated, continuous monitoring model - Set a recurring calendar cadence for revalidation triggered by system changes - Run a mock FDA record request annually to test your response time end to end - Document your ALCOA+ controls formally so they are audit-ready, not just operationally sound #### Audit-Ready: Maintain and Automate Continuous Evidence **Min:** 86 **Max:** 100 **Verdict:** Your electronic records program meets or exceeds typical 21 CFR Part 11 expectations, with strong audit trail coverage, current validation, and proactive anomaly detection. The priority now is maintaining this state as systems change and using your posture as a competitive advantage in customer and partner audits. **Recommendations:** - Automate validation status tracking so new system changes trigger revalidation without manual follow-up - Use your audit-ready posture as a differentiator in customer and supplier qualification audits - Periodically benchmark against evolving FDA guidance to stay ahead of new expectations - Extend the same automated evidence model to adjacent quality and safety compliance programs ## Content **Intro:** 21 CFR Part 11 inspections do not fail on intent, they fail on evidence: can you show a complete, tamper-evident audit trail for the electronic record an investigator picked, and can you produce it fast. This 8-question assessment scores your organization across e-signature validity, audit trail coverage, access control, validation currency, and data integrity monitoring, then places you in one of four readiness bands with specific next steps. It takes under five minutes and gives medical device makers and regulated manufacturers a documented starting point before the next FDA inspection or customer quality audit. **Sections:** #### Audit trail completeness is the single most common finding **Body:** FDA 483 observations related to Part 11 disproportionately cite incomplete or missing audit trails, particularly for systems that were added after the original validation was completed. A shop floor MES upgrade, a new LIMS integration, or a spreadsheet-based workaround for a gap in the primary system are all common sources of audit trail blind spots that investigators specifically look for. **Bullets:** - Audit trail gaps are easier to find during inspection than during internal review - Spreadsheet workarounds outside the validated system are a frequent, avoidable finding - Every system touching a GxP record needs the same audit trail standard, not just the primary one #### Validation currency matters as much as validation existence **Body:** Having a validation package on file is not the same as being validated today. System updates, patches, and configuration changes that are not re-evaluated against the original validation create a documentation gap that investigators treat as equivalent to no validation at all. Risk-based Computer Software Assurance approaches can keep this current without re-running a full validation cycle for every minor change. **Bullets:** - Any patch or configuration change should trigger a documented impact assessment - Risk-based CSA lets you scale validation effort to the actual risk of the change - Outdated validation documentation is treated the same as missing validation by investigators #### Speed of response is itself a compliance signal **Body:** How quickly you can produce a complete electronic record with its audit trail on request signals the maturity of your entire program to an investigator, independent of whether any single control has a gap. Organizations that need weeks to assemble a record set invite deeper scrutiny into every other control, while same-day production builds confidence that carries through the rest of the inspection. **Bullets:** - Same-day record production is achievable with automated export tooling - Slow response to a record request is itself logged as an observation in some inspections - A documented, tested record retrieval process is worth building before you need it **Cta:** Netray builds validated data pipelines and automated audit trail systems for medical device makers and regulated manufacturers, so a record request is a five-minute export instead of a two-week scramble. **Faq:** #### What is 21 CFR Part 11 and who does it apply to? **Answer:** 21 CFR Part 11 is the FDA regulation governing electronic records and electronic signatures used in place of paper records for FDA-regulated processes. It applies to any company, including medical device makers, pharmaceutical manufacturers, and their suppliers, that uses electronic systems to create, modify, or store GxP records. #### What is the difference between traditional CSV and risk-based CSA? **Answer:** Traditional Computer System Validation applies a uniform, exhaustive validation protocol to every system regardless of risk. Risk-based Computer Software Assurance scales validation effort to the actual patient safety and data integrity risk of the system, letting low-risk changes move faster while still documenting the assessment. #### What triggers an FDA 483 observation related to Part 11? **Answer:** The most common triggers are incomplete or missing audit trails, shared or generic system logins, outdated validation documentation after a system change, and an inability to produce a complete record set promptly on request. Investigators specifically probe for gaps introduced by system updates made after initial validation. #### How long should audit trail data be retained under Part 11? **Answer:** Part 11 itself does not set a universal retention period; retention is governed by the predicate rule for the specific record type, such as device history records or batch records, which commonly range from several years to the life of the product plus additional years. Retention policy should be documented per record class. #### Can spreadsheets be used for GxP records under Part 11? **Answer:** Spreadsheets can be used only if they meet the same validation, audit trail, and access control requirements as any other system handling GxP records, which most standard spreadsheet deployments do not meet without significant additional controls. Investigators frequently flag ad hoc spreadsheet use as an unvalidated system finding. ## Search terms part 11 readiness, 21 CFR Part 11 readiness, FDA electronic records compliance, Part 11 audit trail, computer system validation FDA, electronic signature compliance, GxP data integrity assessment, FDA 483 audit trail, medical device compliance assessment --- Talk to an engineer: https://netray.co/contact?intent=erp_ai | Machine catalog: https://netray.co/agent/catalog.json